Terazosin for benign prostatic hyperplasia

Abstract

The available evidence suggests that terazosin improves urinary symptoms and flow measures associated with BPO. Effectiveness is superior to placebo or finasteride, similar to other alpha-blockers but less than TUMT. Adverse effects were generally mild but more frequent than other alpha-blockers and associated with between a two-four fold increase in treatment discontinuation.

Pharmacologic management of urinary incontinence

“…In men who have hypertension and cardiac risk factors, doxazosin monotherapy is associated with a higher incidence of congestive heart failure than are other antihypertensive agents. Terazosin's adverse effects, although generally mild, seem more frequent than other a-blockers' and are associated with a two-to fourfold increase in treatment discontinuation [10].…”

2010 Update: Guidelines for the management of benign prostatic hyperplasia

“…[19][20][21][22][23][24][25][26][27] (Level 1 Evidence, Grade A Recommendation). Alfuzosin, doxazosin, tamsulosin and terazosin are appropriate treatment options for LUTS secondary to BPH.…”

Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia

“…A systematic review of the available randomized controlled trials found that tamsulosin achieved an improvement in symptom scores that ranged from −20% to −48% and an increase in maximum flow rate (Q max ) that ranged from 1.2 to 4.0 ml/s (13-44% improvement) [Wilt et al 2002]. The main adverse effects related to tamsulosin use comprise asthenia, dizziness, rhinitis, symptomatic postural hypotension, ocular disorders [intraoperative floppy iris syndrome (IFIS)] and disorders of ejaculation [Oelke et al 2013].…”